Prostate-Specific Antigen-Retargeted Recombinant Newcastle Disease Virus for Prostate Cancer Virotherapy

Raghunath, Shobana; Samal, Siba K.; Elankumaran, Subbiah

doi:10.1128/jvi.02394-12

Cited by 32 publications

(24 citation statements)

References 47 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NDV could also be modified by incorporation of two transgenes, one coding for the light chain and the other for the heavy chain of a monoclonal antibody interfering with angiogenesis [105]. The transfer of a gene coding for a TAA created a vector with which the immune response could be targeted to a specific TAA in order to compete with the usually stronger response to viral antigens (VA) [106]. For more details regarding these genetically engineered NDVs, see [20].…”

Section: Combining Ndv With Therapeutic Transgenesmentioning

confidence: 99%

Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

Schirrmacher¹

2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

Section: Combining Ndv With Therapeutic Transgenesmentioning

confidence: 99%

Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

Schirrmacher¹

2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

“…The lytic strains can be used for oncolytic therapy, whereas the nonlytic strains can be used as ATV-NDV. Because NDV is a negative strand RNA virus, reverse genetics had to be used for the development of recombinant NDV (35). Most of strains successfully rescued by reverse genetics are lytic strains (36)(37)(38), which are not suitable for the development of ATV-NDV.…”

Section: Discussionmentioning

confidence: 99%

Autologous Tumor Vaccine Modified with Recombinant New Castle Disease Virus Expressing IL-7 Promotes Antitumor Immune Response

Zhao

Sun

et al. 2014

The Journal of Immunology

View full text Add to dashboard Cite

Autologous tumor vaccine modified with nonlytic Newcastle disease virus (ATV-NDV) is a promising vaccine for cancer immunotherapy. IL-7 plays a critical role in lymphocyte development and homeostasis. To improve the efficacy of ATV-NDV, we inserted the murine IL-7 gene into the genome of nonlytic NDV strain LX using reverse genetic system. The insertion of the IL-7 gene neither affected the main features of NDV replication nor its tumor selectivity. The gene product was biologically active and stable. Then we tested the antitumor effects of the autologous tumor vaccine modified with LX/(IL-7) in the murine tumor models. We showed that tumor cells modified with LX/IL-7 induced a strong antitumor activity both in prophylaxis and therapeutic models. The IFN-γ production and the cytotoxicity of tumor-specific CD8+ T cells were significantly enhanced after immunization with tumor cells modified with LX/(IL-7) in both models. Although the tumor-infiltrating CD4+ T cells and CD8+ T cells were both increased and their IFN-γ productions also were upregulated, the antitumor activity of the tumor vaccine modified with LX/(IL-7) was dependent on CD8+ T cells. Our results demonstrated that the autologous tumor vaccine modified with NDV strain LX/(IL-7) could promote the antitumor immune responses mediated by CD8+ T cells and significantly improve the efficacy of the ATV-NDV.

show abstract

“…Cassel and Garrett first observed the oncolytic effect of NDV in 1965, since then NDV has been used extensively as an oncolytic agent in both preclinical and clinical studies (Cassel and Garrett, 1965;Schirrmacher et al, 2001). NDV has been identified and tested in various animal and human models for cancer treatment (Lam et al, 2011;Shobana et al, 2013). Oncolytic properties of NDV emanate from its inherent ability to grow in IFN deficient cells such as tumor cells (Stojdl et al, 2000).…”

Section: Newcastle Disease Virus As An Oncolytic Agentmentioning

confidence: 99%

Newcastle disease virus: Current status and our understanding

et al. 2014

View full text Add to dashboard Cite

Newcastle disease (ND) is one of the highly pathogenic viral diseases of avian species. ND is economically significant because of the huge mortality and morbidity associated with it. The disease is endemic in many third world countries where agriculture serves as the primary source of national income. Newcastle disease virus (NDV) belongs to the family Paramyxoviridae and is well characterized member among the avian paramyxovirus serotypes. In recent years, NDV has lured the virologists not only because of its pathogenic potential, but also for its oncolytic activity and its use as a vaccine vector for both humans and animals. The NDV based recombinant vaccine offers a pertinent choice for the construction of live attenuated vaccine due to its modular nature of transcription, minimum recombination frequency, and lack of DNA phase during replication. Our current understanding about the NDV biology is expanding rapidly because of the availability of modern molecular biology tools and high-throughput complete genome sequencing.

show abstract

Prostate-Specific Antigen-Retargeted Recombinant Newcastle Disease Virus for Prostate Cancer Virotherapy

Cited by 32 publications

References 47 publications

Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

Autologous Tumor Vaccine Modified with Recombinant New Castle Disease Virus Expressing IL-7 Promotes Antitumor Immune Response

Newcastle disease virus: Current status and our understanding

Contact Info

Product

Resources

About